Investor082,
What SIO does with their investment in a pre revenue company will always hinge on their due diligence with regard to time value and opportunity costs. Their primary motive is making money and they will make moves based on that. No one should expect anything less. If their ROI timelines change significantly based on their due diligence then their moves would be expected to reflect this.
What do you think might likely happen when combo results are shared that include Poly ICLC, checkpoint inhibitor and L the L receives approval and the only place to receive combo treatment with Poly ICLC is in the UK?; ). What happens when patients want keytruda or other checkpoint inhibitor to be used in combo with L?; ). Which big pharma blinks first? No one needs an arbitrary March deadline to know that big pharma WILL partner with NWBO. Availability is an issue that longer term only Flaskworks can solve so everyone wants or needs an update about Flaskworks. In the mean time a big money backer or group could make things very interesting. I’ll wait for Linda’s next move after an approval decision then will revisit your March time line. I want to see if she is going to make it difficult for big pharma to wait with a beneficial source of funding. Until then everything hinges on manufacturing preparedness for any big pharma cooperation. Like I have said for a very long time, manufacturing, manufacturing, manufacturing. Best wishes.
Market Data 
Markets 
AI
